Last update 27 Dec 2024
Estriol
Last update 27 Dec 2024
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms (16α,17β)-estra-1,3,5(10)-triene-3,16,17-triol, 1,3,5(10)-Estratriene-3,16-alpha,17beta-triol, 16-alpha-Hydroxyestradiol + [18] |
Target |
Mechanism ERs agonists(Estrogen receptors agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (18 Nov 1960), |
Regulation- |
Login to view timeline
Structure
Molecular FormulaC18H24O3 |
InChIKeyPROQIPRRNZUXQM-ZXXIGWHRSA-N |
CAS Registry50-27-1 |
Related
35
Clinical Trials associated with EstriolEffect of Local Estriol Treatment Before Vaginal Repair Surgery on Vaginal Tissues and Early Postoperative Pelvic Floor Functions
GRACE-trial: a Randomized Active-controlled Trial for vulvovaGinal atRophy in breAst Cancer Patients on Endocrine Therapy.
Correction of Vulvovaginal Atrophy in Postmenopausal Women Using Neodymium Laser Treatment
100 Clinical Results associated with Estriol
Login to view more data
100 Translational Medicine associated with Estriol
Login to view more data
100 Patents (Medical) associated with Estriol
Login to view more data
4,877
Literatures (Medical) associated with Estriol01 Jun 2025Journal of Environmental Sciences
Gene expression profiles of Chinese medaka (Oryzias sinensis) primary hepatocytes in response to estrone (E1), 17β-estradiol (E2) and estriol (E3)
Article
Author: Lv, Junhui ; Reze, Yilihamu ; Zhang, Kailun ; Zhou, Ying ; Zhu, Hua ; Wang, Yue ; Zhang, Zhaobin ; Huai, Narma ; Xie, Zhongtang ; Li, Xiqing
The natural estrogens, including estrone (E1), 17β-estradiol (E2), and estriol (E3), are frequently detected in aquatic environment at relatively high levels. The most commonly used biomarkers for estrogens are mainly expressed in the liver of fish. Analyses of the global gene profiling in fish liver cells under estrogens treatment will provide precise toxicogenomic information of the natural estrogens which is still not well known. In this study, we developed methods for isolation and culture of primary hepatocytes from liver tissue of male Chinese medaka (Oryzias sinensis), and analyzed the global gene expression profiling in the primary hepatocytes treated with E1 (1, 10, and 100 nmol/L), E2 (0.01, 0.1, 1, 10, and 100 nmol/L), and E3 (1, 10, and 100 nmol/L) using RNA-seq. It was found that 175, 248, and 218 genes were differentially expressed in the E1, E2, and E3 groups, respectively. These differentially expressed genes (DEGs) were mainly enriched in Gene Ontology (GO) terms of "response to estradiol", "response to estrogen", and "lipid transport". Of the DEGs, vitellogenin genes, including vtg1, vtg2, and vtg3, were the mostly up-regulated and followed by zona pellucida genes which include zp2.3, zp2l1 and zp3a.2. In addition, genes of slc41a1, zp2.1, esr1, pkd1l1, fam20ca, best3, etc. were also obviously up-regulated by the estrogens in concentration-dependent patterns. RT-qPCR was used to validate the results of RNA-seq and found that vtg2 should be the best biomarker gene for estrogen study, which could well response to natural estrogens and weak estrogenic chemical, propyl 4-hydroxybenzoate.
01 Jan 2025ANALYTICA CHIMICA ACTA
Hydrophilic-lipophilic balance copolymer composite nanofiber as an adsorbent for online solid phase extraction of three estrogens from water samples with column-switching prior to high-performance liquid chromatography
Article
Author: Xu, Ke ; LiQin, C.H.E.N. ; Ze, FANG Zhong ; Tong, X.U. ; Ke, X.U. ; Xu, Tong ; Fang, Zhongze ; Chen, Liqin
BACKGROUND:
In recent years, the increasing accumulation of estrogen pollutants in the environment has raised concerns about their impact on human health, necessitating the development of highly sensitive detection methods for trace pollutant enrichment and analysis in environmental samples. Online pretreatment detection technology offers significant advantages over conventional offline techniques, including high automation, minimal human intervention, and improved efficiency. However, the key to successful implementation lies in the advancement of novel adsorbent materials.
RESULTS:
Herein, we present a novel adsorbent material called polyacrylonitrile-hydrophilic-lipophilic balanced copolymer (PAN-HLB) composite nanofiber prepared via electrospinning for efficient online packed fiber solid phase extraction (PFSPE) of three estrogens from water samples. A rapid and highly sensitive online PFSPE-HPLC-FLD method was developed for the quantification of 17 β-Estradiol (E2), Estriol (E3), and 17-ethinylestradiol (EE2). The curves of the target analytes were prepared with good correlation coefficient values (r2 > 0.9900) in the range of 0.1-2 ng/mL. The limit of detection (S/N = 3) was 0.05 ng/mL, the limit of quantitation (S/N = 10) is 0.1 ng/mL. The recoveries of three estrogens were 94.0 %∼110.3 %, and the precisions (RSD) were less than 5 %. The online PFSPE column, packed with the PAN-HLB composite nanofiber, exhibits exceptional stability and can be effectively reused for a minimum of 100 cycles.
SIGNIFICANCE:
This study presents the successful preparation of PAN-HLB composite nanofiber for the first time, demonstrating their efficacy as an innovative online pretreatment adsorbent. The proposed online pretreatment and detection approach offers remarkable benefits in terms of sensitivity, labor-saving, and cost-effectiveness that make it highly suitable for practical water sample analysis.
01 Jan 2025PSYCHONEUROENDOCRINOLOGY
Growth Differentiation Factor 15 during pregnancy and postpartum as captured in blood, cerebrospinal fluid and placenta: A cohort study on associations with maternal mental health
Article
Author: Frokjaer, Vibe G ; Ekelund, Kim ; Hegaard, Hanne K ; Frokjaer, Vibe G. ; Renault, Kristina M. ; Høgh, Stinne ; Klein, Anders B ; Clemmensen, Christoffer ; Renault, Kristina M ; Bruzzone, Silvia EP ; Bruzzone, Silvia Ep ; Hegaard, Hanne K. ; Borgsted, Camilla ; Klein, Anders B.
INTRODUCTION:
Growth Differentiation Factor 15 (GDF15) increases substantially during pregnancy and is primarily produced by the placenta. Elevated levels of GDF15 have been associated with mental health problems in non-perinatal populations, higher corticosterone levels, and decreased estrogen receptor activity. However, the role of GDF15 in mental health during the perinatal transition remains unknown. This longitudinal study is the first to evaluate pregnancy levels of GDF15 in cerebrospinal fluid (cGDF15), plasma (pGDF15) and placenta GDF15 mRNA, along with mapping plasma GDF15 (pGDF15) level changes from late pregnancy to early postpartum. Moreover, we aimed to evaluate the association between pregnancy cGDF15 levels and cortisol early postpartum, evaluate the association between pregnancy cGDF15 levels and mental health in pregnancy and postpartum, and evaluate the association between pGDF15 and estrogens and high-sensitivity C-reactive protein (CRP).
METHODS:
We included data from 95 women scheduled for a planned cesarean section and obtained cerebrospinal fluid (CSF) and plasma levels of GDF15. We quantified GDF15 mRNA levels in placenta biopsies. Estrogens, high-sensitivity CRP, and mental health measures were further collected on the day or one day before the cesarean section. At five weeks postpartum, mental health measures and saliva samples for cortisol analyses were collected. Correlation analyses for GDF15 in CSF, plasma, and placenta mRNA were performed, along with association analyses for pregnancy cGDF15, Cortisol Awakening Response, and mental health outcomes.
RESULTS:
We demonstrated a strong correlation between cGDF15 and pGDF15 (r=0.52; p<0.001) and found that both cGDF15 and pGDF15 correlated with placenta GDF15 mRNA*placental weight (r=0.62, p<0.001 and r=0.44, p=0.008, respectively). During late pregnancy, both estradiol (E2) and estriol (E3) were significantly associated with pGDF15 levels (E2: p=0.002; E3: p(corrected)<0.001). Finally, we found that cGDF15 levels were not associated with self-reported mental well-being or the Cortisol Awakening Response or absolute cortisol at awakening postpartum.
CONCLUSION:
This novel study points to the unique hormonal landscape during the perinatal transition and the specific role of GDF15 in pregnancy, which appears uncoupled with perinatal mental health and cortisol outcomes. Our data also strongly imply that the overall amount of circulating GDF15 in late pregnancy is closely related to placenta size.
2
News (Medical) associated with Estriol100 Deals associated with Estriol
Login to view more data
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Infertility | CN | - | 01 Jan 2000 |
| Vulvovaginal atrophy | GB | 20 Aug 1982 | |
| Osteoporosis | JP | 28 Dec 1981 | |
| Female Urogenital Diseases | JP | 27 Sep 1972 | |
| Menopausal symptoms | JP | 18 Nov 1960 | |
| Uterine Cervical Erosion | JP | 18 Nov 1960 | |
| Uterine Cervicitis | JP | 18 Nov 1960 | |
| Vaginitis | JP | 18 Nov 1960 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| vaginal mucosa dry | Phase 2 | CZ | 01 Oct 2016 | |
| vaginal mucosa dry | Phase 2 | HU | 01 Oct 2016 | |
| vaginal mucosa dry | Phase 2 | IT | 01 Oct 2016 | |
| vaginal mucosa dry | Phase 2 | ES | 01 Oct 2016 | |
| vaginal mucosa dry | Phase 2 | SE | 01 Oct 2016 | |
| Atrophic Vaginitis | Phase 2 | ES | 16 Oct 2015 | |
| Atrophic Vaginitis | Phase 2 | SE | 16 Oct 2015 | |
| Early Stage Breast Carcinoma | Phase 2 | ES | 16 Oct 2015 | |
| Early Stage Breast Carcinoma | Phase 2 | SE | 16 Oct 2015 | |
| Multiple Sclerosis | Phase 2 | US | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | Breast Feeding c-myc expression | 33 | Combined oral hormonal contraceptive + Placebo | koohllnkms(dfwwcfouut) = sbwyllncpy ldpbxfzjtn (vjwboccmrd, 10.65) | - | 01 Mar 2023 | |
Combined oral hormonal contraceptive + Estriol | koohllnkms(dfwwcfouut) = ithcvavgrc ldpbxfzjtn (vjwboccmrd, 9.88) | ||||||
Phase 3 | 167 | (0.005% Estriol Group) | stvstbveyu(xxgwufykfr) = zpchhbedij drsxgajroo (ndkxrrklwc, vdvfqciguq - njmemwlwqw) View more | - | 11 Dec 2020 | ||
Placebo (Placebo Group) | stvstbveyu(xxgwufykfr) = ejagndzjhd drsxgajroo (ndkxrrklwc, lnlkvjxbci - dlvaoaatja) View more | ||||||
Phase 2 | 283 | (Estriol 0.005%) | ffjfdkhtxn(sofuqposnh) = mcxynqlgcy afvfmeoxry (lpwashljbt, wsbtpelami - jylhtgemkg) View more | - | 25 Sep 2019 | ||
(Estriol 0.002%) | ffjfdkhtxn(sofuqposnh) = uoffpferkw afvfmeoxry (lpwashljbt, wlweymsrwl - jarpfxkicb) View more | ||||||
Phase 2 | 61 | (0.005% Estriol Vaginal Gel) | hxslgljctp(zvnezbbwag) = eheqpcludz hnamckhyyj (afvkkqoman, kavdypbbjj - scucrkrgrw) View more | - | 05 Aug 2019 | ||
Placebo (Placebo Vaginal Gel) | hxslgljctp(zvnezbbwag) = dzowimglfm hnamckhyyj (afvkkqoman, yblwyqnmfi - uzwttynvfe) View more | ||||||
Phase 2 | 123 | (Bevacizumab Spray) | gpucdsbjmw(jjqzqogoic) = ostotmgpgf lnqgkjlpil (gzdrnemkba, zreocnfkrj - xuczjkxula) View more | - | 19 Oct 2018 | ||
(Estriol Spray) | gpucdsbjmw(jjqzqogoic) = cvjahzdfmu lnqgkjlpil (gzdrnemkba, gmkrhrbggl - ujvnowztlh) View more | ||||||
Phase 2 | - | 21 | (Study Arm 1) | tafspsuowv(dlbycvwlqa) = fpxmrrfmud xgnjhslmog (mhroyjpkpk, hrvdomcnno - rhrcsumnyb) View more | - | 16 May 2018 | |
(Study Arm 2) | tafspsuowv(dlbycvwlqa) = bwhqjsdpmr xgnjhslmog (mhroyjpkpk, vitkamuape - rmbmejaxiv) View more | ||||||
Phase 2 | Adjuvant | 70 | Estriol vaginal gel | fsgufggkjr(loskicczbl) = One serious adverse event emerged before the patient initiated treatment alxcogbggu (tkrjzvjesy ) View more | Positive | 15 Feb 2018 | |
Placebo gel | |||||||
Phase 2 | 158 | fomqkorxsu(zttpyptdqy) = qpmiwdddyh gtclymjnjp (igzlggpnuw, bydlxqblfp - ehlbcgicfm) View more | - | 16 Jun 2016 | |||
Placebo+Copaxone (Placebo Capsules Plus Copaxone Injections) | fomqkorxsu(zttpyptdqy) = paujojqsyw gtclymjnjp (igzlggpnuw, xnbjxnzzja - xnwlogxvig) View more | ||||||
Phase 2 | 164 | mobegakszo(qpyequhwhp) = elvsggpwji vfdsefoejd (txpznrryda, 0.17 - 0.37) View more | Positive | 01 Jan 2016 | |||
Placebo | mobegakszo(qpyequhwhp) = jqijwhhfkg vfdsefoejd (txpznrryda, 0.25 - 0.53) View more | ||||||
Not Applicable | - | Vaginal estriol-lactobacilli combination | zsdknwnhuy(ropwwrdkwg) = ohdmajwfuy lpmkeeflbv (ercunccpjn ) View more | - | 04 Mar 2015 |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free